Royal Fund Management’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.87M | Sell |
77,701
-2,807
| -3% | -$73.4K | 0.16% | 156 |
|
|
2026
Q1 | $2.26M | Buy |
80,508
+59,072
| +276% | +$1.57M | 0.21% | 127 |
|
|
2025
Q4 | $534K | Sell |
21,436
-561
| -3% | -$14.1K | 0.05% | 210 |
|
|
2025
Q3 | $560K | Sell |
21,997
-7,158
| -25% | -$177K | 0.07% | 186 |
|
|
2025
Q2 | $707K | Sell |
29,155
-877
| -3% | -$20.5K | 0.07% | 215 |
|
|
2025
Q1 | $761K | Buy |
30,032
+5,319
| +22% | +$139K | 0.08% | 214 |
|
|
2024
Q4 | $656K | Buy |
24,713
+16,249
| +192% | +$441K | 0.06% | 198 |
|
|
2024
Q3 | $245K | Buy |
+8,464
| New | +$247K | 0.01% | 294 |
|
|
2023
Q1 | – | Sell |
-5,094
| Closed | -$261K | – | 284 |
|
|
2022
Q4 | $261K | Sell |
5,094
-37
| -0.7% | -$1.77K | 0.04% | 228 |
|
|
2022
Q3 | $224K | Buy |
5,131
+369
| +8% | +$17.9K | 0.04% | 201 |
|
|
2022
Q2 | $249K | Buy |
4,762
+541
| +13% | +$27.6K | 0.04% | 185 |
|
|
2022
Q1 | $218K | Buy |
4,221
+97
| +2% | +$5.03K | 0.03% | 194 |
|
|
2021
Q4 | $243K | Buy |
+4,124
| New | +$204K | 0.03% | 173 |
|
|
2021
Q3 | – | Sell |
-5,237
| Closed | -$205K | – | 200 |
|
|
2021
Q2 | $205K | Buy |
+5,237
| New | +$204K | 0.03% | 183 |
|
|
2021
Q1 | – | Sell |
-6,348
| Closed | -$233K | – | 193 |
|
|
2020
Q4 | $233K | Buy |
6,348
+594
| +10% | +$21.8K | 0.05% | 153 |
|
|
2020
Q3 | $200K | Buy |
+5,754
| New | +$202K | 0.05% | 162 |
|
|
2020
Q2 | – | Sell |
-4,179
| Closed | -$129K | – | 450 |
|
|
2020
Q1 | $129K | Sell |
4,179
-43,427
| -91% | -$1.48M | 0.05% | 173 |
|
|
2019
Q4 | $1.77M | Sell |
47,606
-9,384
| -16% | -$334K | 0.45% | 56 |
|
|
2019
Q3 | $1.94M | Sell |
56,990
-87,773
| -61% | -$3.19M | 0.54% | 56 |
|
|
2019
Q2 | $5.95M | Buy |
144,763
+5,682
| +4% | +$226K | 1.76% | 20 |
|
|
2019
Q1 | $5.6M | Buy |
139,081
+117,886
| +556% | +$4.72M | 1.79% | 18 |
|
|
2018
Q4 | $877K | Sell |
21,195
-753
| -3% | -$31.3K | 0.36% | 57 |
|
|
2018
Q3 | $917K | Sell |
21,948
-480
| -2% | -$18.5K | 0.29% | 62 |
|
|
2018
Q2 | $772K | Sell |
22,428
-1,603
| -7% | -$54.8K | 0.25% | 64 |
|
|
2018
Q1 | $809K | Sell |
24,031
-541
| -2% | -$18.6K | 0.3% | 63 |
|
|
2017
Q4 | $844K | Sell |
24,572
-807
| -3% | -$27.5K | 0.3% | 54 |
|
|
2017
Q3 | $859K | Sell |
25,379
-4,671
| -16% | -$150K | 0.34% | 51 |
|
|
2017
Q2 | $957K | Sell |
30,050
-150
| -0.5% | -$4.73K | 0.41% | 40 |
|
|
2017
Q1 | $980K | Sell |
30,200
-2,935
| -9% | -$92.5K | 0.47% | 35 |
|
|
2016
Q4 | $1.02M | Buy |
+33,135
| New | +$1.01M | 0.57% | 26 |
|
Other funds holding PFE
CWP
FWIA
ORIO
CNB
Royal Fund Management's PFE Position: Q2 2026 in Review
Royal Fund Management reduced its Pfizer (PFE) stake by 3.5% in Q2 2026, selling an estimated $73.4K and leaving 77,701 shares worth $1.87M. The position accounts for 0.16% of the portfolio, ranked #156.
Royal Fund Management first reported a position in PFE in Q4 2016 and has held it in 30 quarters since. The position peaked at $5.95M in Q2 2019. 705 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Royal Fund Management held 77,701 shares of Pfizer worth $1.87M as of Q2 2026.
- Royal Fund Management sold 2,807 Pfizer shares in Q2 2026, an estimated $73.4K.
- Pfizer made up 0.16% of Royal Fund Management's portfolio in Q2 2026, its #156 holding.
- Royal Fund Management first reported a position in Pfizer in Q4 2016 and has held it in 30 quarters since.
- Royal Fund Management's Pfizer position peaked at $5.95M in Q2 2019.
- 705 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Royal Fund Management's 13F filing for Q2 2026, filed 20 Jul 2026.